Search

Your search keyword '"Gemicioglu, Bilun"' showing total 363 results

Search Constraints

Start Over You searched for: Author "Gemicioglu, Bilun" Remove constraint Author: "Gemicioglu, Bilun"
363 results on '"Gemicioglu, Bilun"'

Search Results

1. Impact of Allergic Rhinitis Control on Work Productivity and Costs: A Real-World Data MASK-air Study

2. Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence–Assisted ARIA Care Pathways (ARIA 2024)

3. MASK-air: An OECD (Organisation for Economic Co-operation and Development) Best Practice for Public Health on Integrated Care for Chronic Diseases

4. Poor Rhinitis and Asthma Control Is Associated With Decreased Health-Related Quality of Life and Utilities: A MASK-air Study

8. Impairment of EQ-5D-5L Domains According to Allergic Rhinitis and Asthma Control: A MASK-air Real-World Study

10. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study

11. Development and validation of an electronic daily control score for asthma (e-DASTHMA): a real-world direct patient data study

12. Cutoff Values of MASK-air Patient-Reported Outcome Measures

13. Physical activity and dietary habits in patients with asthma: How is it related to asthma control?

14. Asthma in the digital world

15. Contributors

16. Academic Productivity of Young People With Allergic Rhinitis: A MASK-air Study

17. The Allergic Rhinitis and Its Impact on Asthma (ARIA) Approach of Value-Added Medicines: As-Needed Treatment in Allergic Rhinitis

18. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study

19. Concurrent validity, cut‐offs and ability to change of patient‐reported outcome measures for rhinitis and asthma in MASK‐air®.

21. Poor rhinitis and asthma control is associated with decreased health-related quality-of-life and utilities: A MASK-air study

22. MASK-air®: An OECD (Organisation for Economic Coordination and Development) Best Practice for Public Health on integrated care for chronic diseases.

24. The predictors of COVID-19 mortality in a nationwide cohort of Turkish patients

25. Relevance of individual bronchial symptoms for asthma diagnosis and control in patients with rhinitis:A MASK-air study

26. Relevance of individual bronchial symptoms for asthma diagnosis and control in patients with rhinitis: A MASK‐air study.

27. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence

30. Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study

31. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

32. The validation of the Turkish version of Asthma Control Test

35. UCRAID (Ukrainian Citizen and refugee electronic support in Respiratory diseases, Allergy, Immunology and Dermatology) action plan

37. Patient‐centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA‐EAACI approach – ARIA‐EAACI Task Force Report

39. In symptomatic patients on as-needed inhaled corticosteroids-formoterol, VAS asthma is associated with small airways resistance.

40. Asthma and rhinitis control in adolescents and young adults: A real‐world MASK‐air study.

44. Pıcturıng Asthma in Turkey: Results from the Turkısh Adult Asthma Regıstry

45. Characteristics of severe asthma patients on biologics: a real-life European registry study

46. Evaluation of Real-World Mepolizumab Use in Severe Asthma across Europe - the SHARP experience with privacy-preserving federated analysis

47. Digitally-enabled, patient-centred care in rhinitis and asthma multimorbidity: The ARIA-MASK-air approach.

48. Consistent trajectories of rhinitis control and treatment in 16,177 weeks : the MASK-air® longitudinal study

49. Patient-centered digital biomarkers for allergic respiratory diseases and asthma:The ARIA-EAACI approach – ARIA-EAACI Task Force Report

50. Patient‐centred digital biomarkers for allergic respiratory diseases and asthma: the ARIA‐EAACI approach

Catalog

Books, media, physical & digital resources